Collegium Pharmaceutical, Inc. (COLL)

Market Cap	939.45M
Revenue (ttm)	599.25M
Net Income (ttm)	88.59M
Shares Out	32.25M
EPS (ttm)	2.16
PE Ratio	13.47
Forward PE	4.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	280,174
Open	30.02
Previous Close	29.75
Day's Range	28.77 - 30.04
52-Week Range	28.39 - 42.29
Beta	0.82
Analysts	Strong Buy
Price Target	43.60 (+49.67%)
Earnings Date	Feb 27, 2025

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a bucc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 197
• Stock Exchange: NASDAQ
• Ticker Symbol: COLL
• Website: https://www.collegiumpharma.com

Analyst Forecast

According to 5 analysts, the average rating for COLL stock is "Strong Buy." The 12-month stock price forecast is $43.6, which is an increase of 49.67% from the latest price.

Price Target

$43.6

(49.67% upside)

Analyst Consensus: Strong Buy